Finance is the field that deals with the management, creation, and study of money, investments, and other financial instruments. It encompasses the processes of acquiring funds, investing those funds, and managing financial resources over time, while considering the risks involved. Finance is broadly categorized into three areas: personal finance, corporate finance, and public finance.
Personal finance involves managing individual or household finances, including budgeting, saving, investing, and planning for future expenses such as retirement or education. Corporate finance focuses on how companies manage their financial activities, including capital structure, funding strategies, and investment decisions, aimed at maximizing shareholder value. Public finance deals with the financial activities of governments, including taxation, government expenditures, and the budgeting process.
Overall, finance plays a critical role in the functioning of economies by facilitating the allocation of resources, supporting investments, and allowing for the efficient distribution of capital. It also includes mechanisms for analyzing financial data, making informed decisions, and understanding financial markets and institutions.
Edesa Biotech appoints Peter J. Weiler as the new CFO, effective May 1, 2025, signaling a strategic shift. Weiler brings a robust track record in biotech and pharma, previously leading…
Edesa Biotech has appointed Peter J. Weiler as the new Chief Financial Officer, marking a pivotal moment for the company's growth and innovation. Weiler brings extensive experience in the pharmaceutical…
Peter J. Weiler appointed as Chief Financial Officer of Edesa Biotech, succeeding Stephen Lemieux. Weiler's leadership experience includes roles at Exzell Pharma, Biosyent Inc., and Cipher Pharmaceuticals. His background is…
Edesa Biotech appoints Peter J. Weiler as the new Chief Financial Officer, effective May 2025, succeeding Stephen Lemieux. Weiler brings extensive experience in corporate finance and strategic development from Exzell…
The appointment of Peter J. Weiler as CFO marks a strategic shift for Edesa Biotech, effective May 1, 2025. Weiler brings extensive experience from roles at Exzell Pharma, Biosyent Inc.,…
Early-stage biotech companies, including Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics, faced significant stock declines, with Biohaven down 35.3% in March's closing quarter. Biotech firms, often investment-heavy and loss-making, are struggling…
The resignation of FDA vaccine official Peter Marks has unsettled the U.S. biotechnology sector, provoking investor anxiety and a significant stock downturn. The S&P 500 biotechnology ETF plunged by 4.9%,…
Asia's financial landscape presents both challenges and opportunities amid global economic uncertainties. Penny stocks offer high risk and high reward, acting as potential wildcards for investors. Yangzijiang Shipbuilding (Holdings) shows…
Marker Therapeutics is highly rated by Canaccord Genuity for its innovative cancer cell therapies, aiming for an target price from . Krystal Biotech garners a strong buy from Jefferies, targeting…
Krystal Biotech is experiencing a significant rise in short interest, with 14.58% of its shares sold short. This increase signifies a shift in investor sentiment, implying expectations of a short-term…